ClinicalTrials.gg
Enrolling by invitationNCT07671313Updated Nov 17, 2026

Online Pain Education for Crohn's Disease and Ulcerative Colitis

An interventional study of Empowered Relief and Living Better with Chronic Pain in Crohn's Disease, Ulcerative Colitis (UC) and Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis), sponsored by Cedars-Sinai Medical Center. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Cedars-Sinai Medical Center · Not applicable, Interventional, and Treatment

How we know

Updated Nov 17, 2026Now Enrolling by invitationStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Crohn Disease by Cedars-Sinai Medical Center — 2 open to participants now, 2 under way, none of them phase 3. Crohn Disease · Cedars-Sinai Medical Center.

Started
2026
the only one that year
No phase
4 of 10
1 open now
Registered
10th of 10
by date

Among the 10 studies in Crohn Disease by Cedars-Sinai Medical Center, this one is the only one that started in 2026, is one of 4 with no phase, and was the 10th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

2 of the 10 studies in Crohn Disease by Cedars-Sinai Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Crohn Disease by Cedars-Sinai Medical Center, or all of them as a file.
02

Study summary

Through a pilot randomized controlled trial (RCT), we aim to test the feasibility and preliminary impact of two online pain educations programs among adult patients with inflammatory bowel disease (IBD) who experience chronic pain. Each online program can be accessed on the patient's personal device, and will take up to 2 hours to complete. Clinical outcomes (pain intensity, pain interference, quality of life) will be assessed via online surveys at baseline and then weekly for 8-weeks post-treatment.

03

Conditions studied

  • Crohn's Disease
  • Ulcerative Colitis (UC)
  • Inflammatory Bowel Disease (Crohn's Disease; Ulcerative Colitis)

Keywords

  • Pain Education
  • Chronic pain
04

Who can participate

The criteria were revised on the registry on Oct 26, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Physician-confirmed diagnosis of Crohn's disease or ulcerative colitis
  • Chronic pain (visceral and/or somatic) related to IBD for at least 3 months
  • NIH PROMIS Pain Interference scale T-score ≥60
  • Medically stable, defined as:

    1. No acute IBD-related hospitalization within the past 3 months; AND
    2. No planned IBD surgery or planned therapeutic escalation within the next 2 months, including initiation of a new advanced therapy, dose escalation or switch of advanced therapy, or taper
  • Able to understand and complete questionnaires independently in English
  • Access to an internet-enabled device for online surveys and intervention access.

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment or other condition that, in the opinion of the investigators, would interfere with protocol participation
  • Current use of standing opioid medications, given the often severe impact of opioids on GI motility and potential for pharmacological visceral hyperalgesia
  • Prior participation in cognitive behavioral therapy (CBT) specifically targeting chronic IBD-related pain
  • Taken any oral medications for IBD or any other condition in the past 2 months (including prednisone, prednisolone, and methylprednisolone [Medrol])
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Empowered Relief

    Participants randomized to the Empowered Relief arm will be scheduled to attend a 2-hour, live-online group Empowered Relief session. Empowered Relief sessions will be conducted via Zoom. Attendance of the Empowered Relief session will be monitored by study staff throughout the 2-hour session. Following the Empowered Relief session, participants in this arm will be provided with access to the 20-minute binaural audio relaxation app the that accompanies the Empowered Relief program and promotes calm through brainwave entrainment. Participants will be instructed to utilize the binaural audio app daily for the 8-weeks following the completion of the Empowered Relief session.

    Behavioral: Empowered Relief

  • Active comparator
    Living Better with Chronic Pain

    Living Better with Chronic Pain provides education on: (i) chronic pain mechanisms, (ii) nutrition and weight management, (iii) physical activity, (iv) working with healthcare providers, (v) informed treatment decisions, and (vi) medication safety. Participants randomized to the Living Better with Chronic Pain arm will be sent a link to access the \~1-hour online recording. Completion of the entire Living Better with Chronic Pain video will be monitored and confirmed by study staff.

    Behavioral: Living Better with Chronic Pain

Interventions

  • BehavioralEmpowered Relief

    Empowered Relief is an online pain education program. Empowered Relief 'compresses' key cognitive behavioral therapy skills, mindfulness principles, and pain neuroscience education into a highly pragmatic, scalable, single 2-hour session. Taught via Zoom by certified instructors to large groups of patients, it teaches participants to identify unhelpful pain-related thoughts, manage physiological hyperarousal, and build coping skills through cognitive reframing, guided relaxation, and self-soothing techniques. Participants receive a 20-minute binaural audio relaxation app that promotes calm through brainwave entrainment.

  • BehavioralLiving Better with Chronic Pain

    Living Better with Chronic Pain is a 2-hour online health program that provides education regarding chronic pain mechanisms, nutrition and weight management, physical activity, working with healthcare providers, informed treatment decisions, and medication safety.

06

What researchers measure

Primary outcomes

  1. PROMIS Pain Interference

    Pain interference as measured by the validated 8-item PROMIS Pain Interference (PROMIS-PI) scale. It assesses self-reported consequences of pain on relevant aspects of one's life, including the extent to which pain hinders engagement with social, cognitive, emotional, physical, and recreational activities. Pain Interference also incorporates items probing sleep and enjoyment in life. This instrument is universal, rather than disease-specific. The recall period for this scale is 7 days.

    Time frame: Baseline, then weekly post-treatment (Weeks 1-8)

Secondary outcomes

  1. PROMIS Pain Intensity

    Pain intensity as measured by the validated 1-item PROMIS Pain Intensity Numeric Rating Scale (NRS). It asks how one would rate their pain on average over the last 7 days, on a scale of 0 to 10.

    Time frame: Baseline, then weekly post-treatment (Weeks 1-8)

  2. PROMIS Abdominal Pain

    Abdominal pain as measured by the validated 5-item PROMIS Abdominal Pain scale. PROMIS Abdominal Pain assesses the severity of belly pain over the past 7 days. This instrument is universal, rather than disease-specific.

    Time frame: Baseline, then weekly post-treatment (Weeks 1-8)

  3. Pain Catastrophizing Scale

    Pain catastrophizing as measured by the validated 13-item Pain Catastrophizing Scale (PCS). It assesses the types of thoughts and feeling that one has when in pain. This scale does not have a specified recall period, but asks for one to review various statements describing different thoughts and feelings that may be associated with pain, and respond based on when experiencing pain previously.

    Time frame: Baseline, then at Weeks 4 and 8 post-treatment

  4. Pain Self-Efficacy

    Pain self-efficacy as measured by the validated 10-item Pain Self-Efficacy Questionnaire (PSEQ). This scale does not have a specified recall period, but asks for one to rate on a scale of 0 to 6 how confident they are that they can do various things at present, despite the pain.

    Time frame: Baseline, then at Weeks 4 and 8 post-treatment

  5. Inflammatory Bowel Disease Disability Index

    The Inflammatory Bowel Disease Disability Index is a validated, disease-specific measure that assesses the impact of Crohn's disease and ulcerative colitis on daily functioning, including physical health, body functions, activities, participation, and overall disability.

    Time frame: Baseline, then at Weeks 4 and 8 post-treatment

  6. IBD Control Questionnaire

    IBD symptoms as measured by the validated 8-item and 1-question visual analog scale (VAS) IBD Control questionnaire. It assesses perceived control over symptoms, usefulness of current treatment, and impact of IBD on various domains over the past 2 weeks.

    Time frame: Baseline, then at Weeks 4 and 8 post-treatment

Other outcomes

  1. Pain Location Assessment

    Pain location as measured by a 1-item Pain Location Assessment questionnaire which asks one to select from a list all of the locations on the body where they have experienced pain in the last 7 days.

    Time frame: Baseline, then weekly post-treatment (Weeks 1-8)

  2. PROMIS Sleep Disturbance

    Sleep disturbance as measured by the validated 4-item PROMIS Sleep Disturbance questionnaire. It assesses self-reported perceptions of sleep quality, sleep process, and restoration associated with sleep. The recall period for this scale is 7 days.

    Time frame: Baseline, then at Weeks 4 and 8 post-treatment

  3. PROMIS Anxiety

    Perceived anxiety as measured by the the validated 8-item PROMIS Emotional Distress - Anxiety scale. It assesses self-reported fear, anxious misery, and hyperarousal. The recall period for this scale is 7 days.

    Time frame: Baseline, then at Weeks 4 and 8 post-treatment

  4. PROMIS Depression

    Perceived depression as measured by the the validated 8-item PROMIS Emotional Distress - Depression scale. It assesses self-reported negative mood, views of self, and social cognition. The recall period for this scale is 7 days.

    Time frame: Baseline, then at Weeks 4 and 8 post-treatment

  5. Treatment Appraisal and Satisfaction

    Treatment appraisal and satisfaction as measured by a 20-item Treatment Appraisal and Satisfaction Survey. It assess usability, relevance, usefulness, and how likely one is to recommend the program to others.

    Time frame: Day 1 post-treatment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jul 2027, 8 months later.

Of 290 non-industry interventional studies with no phase under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's planned 8 months is below that.

Counting every sponsor, half of 302 studies reached it within 45 months; a quarter within 21 and three quarters within 65.

Start moved twice since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, last on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jun 26, 2026
StartEst.
Nov 2026was Aug 2026
Primary completionEst.
Jul 2027
CompletionEst.
Sep 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 17, 2026
Start date
Aug 2026→Nov 2026
moved 2 times, Oct 26, 2026 – Nov 17, 2026
Eligibility
1 exclusion criterion added
What changed in the criteria
Exclusion criteria
  • AddedTaken any oral steroid medications for IBD or any other condition in the past 2 months (including prednisone, prednisolone, and methylprednisolone [Medrol])
Oct 26, 2026
Contact
No study contact listed any more: removed Z•••@cshs.org · •••0699; removed S•••@cshs.org · •••6721
Nov 17, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Cedars-Sinai Medical Center · Los Angeles, United StatesContact removed Z•••@cshs.org · •••0699Contact removed (no phone or email listed)
Nov 17, 2026
Show all 2 updates
  1. Nov 17, 2026
    Not yet recruiting→Enrolling by invitation
    Start date Oct 2026→Nov 2026
    Contact No study contact listed any more: removed Z•••@cshs.org · •••0699; removed S•••@cshs.org · •••6721
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Cedars-Sinai Medical Center · Los Angeles, United StatesContact removed Z•••@cshs.org · •••0699Contact removed (no phone or email listed)
  2. Oct 26, 2026
    Start date Aug 2026→Oct 2026
    Eligibility 1 exclusion criterion added
    What changed in the criteria
    Exclusion criteria
    • AddedTaken any oral steroid medications for IBD or any other condition in the past 2 months (including prednisone, prednisolone, and methylprednisolone [Medrol])
    + 3 other changes: description, conditions and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07671313
Responsible party
Christopher Almario (Associate Professor of Medicine, Cedars-Sinai Medical Center) — Principal investigator
First posted
Jun 26, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Christopher V Almario, MD, MSHPM
principal investigator · Cedars-Sinai Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion